Comprehensive Stock Comparison
Compare OS Therapies Incorporated (OSTX) vs ImmunityBio, Inc. (IBRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | OSTX | Beta 0.81 vs IBRX's 1.39 |
| Dividends | OSTX | 100.0% yield; 1-year raise streak; IBRX pays no meaningful dividend |
| Momentum (1Y) | IBRX | +197.3% vs OSTX's -10.9% |
| Efficiency (ROA) | IBRX | -93.2% ROA vs OSTX's -204.2% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
OS Therapies is a clinical-stage biopharmaceutical company developing novel treatments for osteosarcoma and other solid tumors. It aims to generate revenue through future drug sales and potential licensing deals — primarily from its lead candidate OST-HER2 (an off-the-shelf immunotherapy) and its tunable antibody-drug conjugate platform. The company's competitive advantage lies in its specialized focus on osteosarcoma — a rare pediatric cancer with limited treatment options — and its proprietary plug-and-play ADC technology with pH-sensitive linkers.
ImmunityBio is a clinical-stage biotechnology company developing immunotherapies and vaccines for cancers and infectious diseases. It generates revenue primarily through research collaborations and licensing agreements — though as a pre-commercial biotech, it currently relies heavily on equity financing and grants to fund its clinical trials. The company's competitive advantage lies in its integrated immunotherapy platform that combines multiple immune system activation approaches — including antibody cytokine fusion proteins, natural killer cells, and T-cell therapies — which could potentially create synergistic treatment effects.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
IBRX leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
IBRX and OSTX operate at a comparable scale, with $83M and $0 in trailing revenue.
| Metric | OSTXOS Therapies Inco… | IBRXImmunityBio, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $83M |
| EBITDAEarnings before interest/tax | -$19M | -$245M |
| Net IncomeAfter-tax profit | -$18M | -$349M |
| Free Cash FlowCash after capex | -$13M | -$324M |
| Gross MarginGross profit ÷ Revenue | — | +94.8% |
| Operating MarginEBIT ÷ Revenue | — | -3.2% |
| Net MarginNet income ÷ Revenue | — | -4.2% |
| FCF MarginFCF ÷ Revenue | — | -3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +4.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.7% | +40.8% |
Valuation Metrics
| Metric | OSTXOS Therapies Inco… | IBRXImmunityBio, Inc. |
|---|---|---|
| Market CapShares × price | $49M | $9.6B |
| Enterprise ValueMkt cap + debt − cash | $43M | $10.0B |
| Trailing P/EPrice ÷ TTM EPS | -2.83x | -15.77x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 653.30x |
| Price / BookPrice ÷ Book value/share | 37.81x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), IBRX scores 4/9 vs OSTX's 3/9, reflecting mixed financial health.
| Metric | OSTXOS Therapies Inco… | IBRXImmunityBio, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -3.9% | — |
| ROA (TTM)Return on assets | -2.0% | -93.2% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -7.5% | -88.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$6M | $361M |
| Cash & Equiv.Liquid assets | $6M | $143M |
| Total DebtShort + long-term debt | $0 | $504M |
| Interest CoverageEBIT ÷ Interest expense | -2418.83x | -2.48x |
Total Returns (with DRIP)
A $10,000 investment in OSTX five years ago would be worth $5,857 today (with dividends reinvested), compared to $2,937 for IBRX. Over the past 12 months, IBRX leads with a +197.3% total return vs OSTX's -10.9%. The 3-year compound annual growth rate (CAGR) favors IBRX at 58.8% vs OSTX's -16.3% — a key indicator of consistent wealth creation.
| Metric | OSTXOS Therapies Inco… | IBRXImmunityBio, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +9.7% | +384.2% |
| 1-Year ReturnPast 12 months | -10.9% | +197.3% |
| 3-Year ReturnCumulative with dividends | -41.4% | +300.8% |
| 5-Year ReturnCumulative with dividends | -41.4% | -70.6% |
| 10-Year ReturnCumulative with dividends | -41.4% | +42.2% |
| CAGR (3Y)Annualised 3-year return | -16.3% | +58.8% |
Risk & Volatility
OSTX is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than IBRX's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IBRX currently trades 78.7% from its 52-week high vs OSTX's 57.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OSTXOS Therapies Inco… | IBRXImmunityBio, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 1.39x |
| 52-Week HighHighest price in past year | $2.57 | $12.43 |
| 52-Week LowLowest price in past year | $1.12 | $1.83 |
| % of 52W HighCurrent price vs 52-week peak | +57.2% | +78.7% |
| RSI (14)Momentum oscillator 0–100 | 57.9 | 65.0 |
| Avg Volume (50D)Average daily shares traded | 510K | 32.7M |
Analyst Outlook
OSTX is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | OSTXOS Therapies Inco… | IBRXImmunityBio, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $11.00 |
| # AnalystsCovering analysts | — | 5 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $1.50 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 24 | Feb 26 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | 100 | 55.38 | -44.6% |
| ImmunityBio, Inc. (IBRX) | 100 | 127.97 | +28.0% |
OS Therapies Incorp… (OSTX) returned -41% over 5 years vs ImmunityBio, Inc. (IBRX)'s -71%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | $0.00 | $0.00 | — |
| ImmunityBio, Inc. (IBRX) | $236000.00 | $15M | +6147.9% |
ImmunityBio, Inc.'s revenue grew from $0M (2015) to $15M (2024) — a 58.3% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| OS Therapies Incorp… (OSTX) | -0 | -0.52 | -74185.7% |
| ImmunityBio, Inc. (IBRX) | -0.73 | -0.62 | +15.1% |
ImmunityBio, Inc.'s EPS grew from $-0.73 (2015) to $-0.62 (2024).
Chart 4Free Cash Flow — 5 Years
OS Therapies Incorporated generated $-7M FCF in 2024 (-65% vs 2021). ImmunityBio, Inc. generated $-398M FCF in 2024 (-29% vs 2021).
OSTX vs IBRX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is OSTX or IBRX a better buy right now?
Analysts rate ImmunityBio, Inc. (IBRX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OSTX or IBRX?
Over the past 5 years, OS Therapies Incorporated (OSTX) delivered a total return of -41.4%, compared to -70.6% for ImmunityBio, Inc. (IBRX). A $10,000 investment in OSTX five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: IBRX returned +42.2% versus OSTX's -41.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OSTX or IBRX?
By beta (market sensitivity over 5 years), OS Therapies Incorporated (OSTX) is the lower-risk stock at 0.81β versus ImmunityBio, Inc.'s 1.39β — meaning IBRX is approximately 73% more volatile than OSTX relative to the S&P 500.
04Which has better profit margins — OSTX or IBRX?
OS Therapies Incorporated (OSTX) is the more profitable company, earning 0.0% net margin versus -28.0% for ImmunityBio, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OSTX leads at 0.0% versus -23.3% for IBRX. At the gross margin level — before operating expenses — IBRX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — OSTX or IBRX?
In this comparison, OSTX (100.0% yield) pays a dividend. IBRX does not pay a meaningful dividend and should not be held primarily for income.
06Is OSTX or IBRX better for a retirement portfolio?
For long-horizon retirement investors, OS Therapies Incorporated (OSTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.81), 100.0% yield). Both have compounded well over 10 years (OSTX: -41.4%, IBRX: +42.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between OSTX and IBRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: OSTX is a small-cap income-oriented stock; IBRX is a small-cap quality compounder stock. OSTX pays a dividend while IBRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.